2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes
作者:Maurice J. van Eis、Jean-Pierre Evenou、Philipp Floersheim、Christoph Gaul、Sandra W. Cowan-Jacob、Lauren Monovich、Gabriele Rummel、Walter Schuler、Wilhelm Stark、Andre Strauss、Anette von Matt、Eric Vangrevelinghe、Juergen Wagner、Nicolas Soldermann
DOI:10.1016/j.bmcl.2011.10.025
日期:2011.12
The present study describes a novel series of ATP-competitive PKC inhibitors based on the 2,6-naphthyridine template. Example compounds potently inhibit the novelProteinKinaseC (PKC) isotypes δ, ε, η, θ (in particular PKCε/η, and display a 10–100-fold selectivity over the classical PKC isotypes. The prototype compound 11 was found to inhibit PKCθ-dependent pathways in vitro and in vivo. In vitro
The present invention provides a compound formula I: (formula I) said compound is inhibitor of selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example MARK1/2/3, PKD-1/2/3, PKN-1/2, CDK-9, CaMKII, ROCK-I/II, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. Finally, the present invention also provides a pharmaceutical composition.
[2,6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS
申请人:Novartis AG
公开号:EP2144909B1
公开(公告)日:2011-03-23
[EN] [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS<br/>[FR] [2,6]NAPHTHYRIDINES UTILES EN TANT QU'INHIBITEURS DES PROTEINES KINASES
申请人:NOVARTIS AG
公开号:WO2008122615A1
公开(公告)日:2008-10-16
[EN] The present invention provides a compound of formula I: (formula I) said compound is inhibitor of selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example MARK1/2/3, PKD-1/2/3, PKN-1/2, CDK-9, CaMKII, ROCK-I/II, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. Finally, the present invention also provides a pharmaceutical composition. [FR] L'invention concerne un composés de formule I : (formule I), utile en tant qu'inhibiteur d'un sous-ensemble sélectif de kinases appartenant à la famille des kinases AGC ou calmoduline, telles que MARK1/2/3, PKD-1/2/3, PKN-1/2, CDK-9, CaMKII, ROCK-I/II, inhibiteurs de la phosphorylation d'histone désacétylase (HDAC) ou inhibiteurs d'autres kinases. L'invention concerne également une composition pharmaceutique associée.